Lakefront Biotherapeutics (LKFT) Stock Forecast: StockMap's 2-Week Call
LKFT stock forecast: StockMap's model leans Outperform on Lakefront Biotherapeutics for the two weeks after the Nov 19 close, toward LKFT doing better than the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 3 of 3 two-week windows on LKFT since Oct 8; by chance, a call on the same dates was right 58% of the time.
Lakefront Biotherapeutics last closed at $33.39, -2.00% on the session.
Against the IVW growth benchmark the position is +0.33% over the forecast window.
Lakefront Biotherapeutics' market cap is $2.15B as of November 19, 2026.
Leans up ↗: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 21 (too close to call).
Where LKFT sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 10 bullish and 5 bearish.
Agreement across those insights is 67%.
8 daily calls for LKFT so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Lakefront Biotherapeutics in the 98th percentile on valuation and the 79th percentile on return on equity, where 100 is best.
Lakefront Biotherapeutics is classified under Health Care / Biotechnology.
StockMap tracks Lakefront Biotherapeutics as the 81st largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Lakefront Biotherapeutics ranks 15th of 394 in the group, against a group median of -0.27.